J. Fraser Wright

Stanford University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

50h-index17.2kcitations120works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(74), Viral Infectious Diseases and Gene Expression in Insects(40), CRISPR and Genetic Engineering(31), CAR-T cell therapy research(28), RNA Interference and Gene Delivery(17)

Publications120 total

neurostuff/NiMARE: 0.9.0
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
neurostuff/NiMARE: 0.8.1
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
neurostuff/NiMARE: 0.8.0
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
neurostuff/NiMARE: 0.8.0rc1
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Improved production and quality of lentiviral vectors by major-splice-donor mutation and co-expression of a novel U1 snRNA-based enhancer
Heliyon·2025· 1 citedOpen Access
The promising potential of gene therapy for diabetes mellitus
Nature Reviews Endocrinology·2024· 8 cited
THE TETRAVECTA™ SYSTEM: A NEW TOOL KIT ENHANCING LENTIVIRAL VECTOR PRODUCTION FOR THE NEXT GENERATION OF GENE THERAPIES
Cytotherapy·2024· 1 cited
A novel FOXP3 knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products
Molecular Therapy — Methods & Clinical Development·2024Open Access
Improved Production and Quality of Lentiviral Vectors By Major-Splice-Donor Mutation and Co-Expression of a Novel U1 Snrna-Based Enhancer
SSRN Electronic Journal·2024· 3 citedOpen Access
A novel FOXP3 knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products
Molecular Therapy — Methods & Clinical Development·2023· 10 citedOpen Access
AAV vector production: Troublesome host innate responses in another setting
Molecular Therapy — Methods & Clinical Development·2023· 1 citedOpen Access
Re-administration of AAV vectors by masking with host albumin: A Goldilocks hypothesis
Molecular Therapy·2023· 3 citedOpen Access
AAV vector production: Troublesome host innate responses in another setting
Molecular Therapy — Methods & Clinical Development·2023· 8 citedOpen Access
AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities
Molecular Therapy·2022· 16 citedOpen Access
Design of experiments as a decision tool for cell therapy manufacturing
Cytotherapy·2022· 9 cited
The intersection of vector biology, gene therapy, and hemophilia
Research and Practice in Thrombosis and Haemostasis·2021· 21 citedOpen Access
Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease
Science Translational Medicine·2021· 150 citedOpen Access
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Frontiers in Immunology·2021· 107 citedOpen Access
Quality Control Testing, Characterization and Critical Quality Attributes of Adeno‐Associated Virus Vectors Used for Human Gene Therapy
Biotechnology Journal·2020· 77 cited
Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease
International Journal of Toxicology·2020· 12 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Katherine A. High(20), Federico Mingozzi(13), Albert M. Maguire(9), Francesca Simonelli(8), Kathleen Marshall(8), Alberto Auricchio(8), Jean Bennett(8), Shangzhen Zhou(8), Bernd Hauck(7), Valder R. Arruda(7), Olga Zelenaia(7), Eric A. Pierce(6), Jeannette Bennicelli(6), Junwei Sun(6), Daniel C. Chung(6), Xiaosong Zhu(5), Jennifer Wellman(5), Daniel J. Hui(5), Yifeng Chen(5), Sandro Banfi(4)